A Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy
A Phase 1 Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy
Sponsor: SynCore Biotechnology Co., Ltd.
A PHASE1 clinical study on Solid Tumors, this trial is completed. The trial is conducted by SynCore Biotechnology Co., Ltd. and has accumulated 10 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE1
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Nov 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
-
Oct 2017 — Nov 2017 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Feb 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Apr 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- SynCore Biotechnology Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .